STOCK TITAN

[8-K] Sabra Healthcare REIT, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.

The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.

Magnite, Inc. (MGNI) ha depositato un Modulo 144 indicando la prevista vendita di 9.289 azioni ordinarie per un valore approssimativo di 204.358 $ al prezzo di mercato corrente. Le azioni sono state originariamente acquisite il 15/02/2024 come azioni vincolate direttamente dall'emittente e la vendita sarà eseguita tramite Morgan Stanley Smith Barney LLC intorno al 30/06/2025. Le azioni totali in circolazione sono riportate pari a 141.110.559, quindi la vendita proposta rappresenta meno dello 0,01% del flottante.

Il deposito indica David Buonasera come azionista venditore, che ha già ceduto 12.395 azioni negli ultimi tre mesi per un ricavo lordo di 194.776,59 $. Sebbene gli importi in dollari siano modesti rispetto alla capitalizzazione di mercato di Magnite, vendite consecutive da parte di insider possono generare preoccupazioni tra alcuni investitori. Il modulo non contiene dati operativi o finanziari né affermazioni sui fondamentali di Magnite; si limita a divulgare l’intenzione dell’insider di vendere ai sensi della Regola 144.

Magnite, Inc. (MGNI) presentó un Formulario 144 indicando una venta planificada de 9,289 acciones comunes por un valor aproximado de $204,358 al precio de mercado vigente. Las acciones fueron adquiridas originalmente el 15/02/2024 como acciones restringidas directamente del emisor y se ejecutarán a través de Morgan Stanley Smith Barney LLC alrededor del 30/06/2025. El total de acciones en circulación se reporta en 141,110,559, por lo que la venta propuesta representa menos del 0.01% del flotante.

El documento lista a David Buonasera como el accionista vendedor, quien ya ha vendido 12,395 acciones en los últimos tres meses por ingresos brutos de $194,776.59. Aunque las cantidades en dólares son modestas en relación con la capitalización de mercado de Magnite, ventas consecutivas por parte de insiders pueden generar preocupaciones en algunos inversores. El formulario no contiene datos operativos o financieros ni hace afirmaciones sobre los fundamentos de Magnite; simplemente revela la intención del insider de vender bajo la Regla 144.

Magnite, Inc. (MGNI)는 9,289주의 보통주를 약 $204,358 상당으로 매도할 계획임을 나타내는 Form 144를 제출했습니다. 해당 주식은 2024년 2월 15일 발행사로부터 직접 제한 주식으로 취득되었으며, 2025년 6월 30일경 Morgan Stanley Smith Barney LLC를 통해 매도될 예정입니다. 총 발행 주식 수는 141,110,559주로 보고되어 있으며, 이번 매도는 유통 주식의 0.01% 미만에 해당합니다.

신고서에는 매도 주주로 David Buonasera가 명시되어 있으며, 그는 지난 3개월 동안 이미 12,395주를 매도하여 총 $194,776.59의 수익을 올렸습니다. 금액은 Magnite의 시가총액에 비해 적은 편이지만, 연속적인 내부자 매도는 일부 투자자들에게 우려를 불러일으킬 수 있습니다. 이 양식은 운영 또는 재무 성과 데이터가 포함되어 있지 않으며, Magnite의 기본적인 사항에 대해 어떠한 주장도 하지 않고 오로지 내부자의 매도 의도를 Rule 144에 따라 공개합니다.

Magnite, Inc. (MGNI) a déposé un formulaire 144 indiquant la vente prévue de 9 289 actions ordinaires d'une valeur d'environ 204 358 $ au prix du marché en vigueur. Les actions ont été initialement acquises le 15/02/2024 en tant qu'actions restreintes directement auprès de l'émetteur et seront vendues via Morgan Stanley Smith Barney LLC aux alentours du 30/06/2025. Le nombre total d'actions en circulation est rapporté à 141 110 559, ce qui signifie que la vente proposée représente moins de 0,01 % du flottant.

Le document mentionne David Buonasera comme actionnaire vendeur, qui a déjà cédé 12 395 actions au cours des trois derniers mois pour un produit brut de 194 776,59 $. Bien que les montants en dollars soient modestes par rapport à la capitalisation boursière de Magnite, des ventes consécutives d'initiés peuvent susciter des inquiétudes chez certains investisseurs. Le formulaire ne contient aucune donnée opérationnelle ou financière et ne fait aucune déclaration sur les fondamentaux de Magnite ; il se limite à divulguer l'intention de l'initié de vendre conformément à la règle 144.

Magnite, Inc. (MGNI) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 9.289 Stammaktien im Wert von etwa 204.358 $ zum aktuellen Marktpreis anzeigt. Die Aktien wurden ursprünglich am 15.02.2024 als eingeschränkte Aktien direkt vom Emittenten erworben und sollen etwa am 30.06.2025 über Morgan Stanley Smith Barney LLC verkauft werden. Die Gesamtzahl der ausstehenden Aktien wird mit 141.110.559 angegeben, sodass der geplante Verkauf weniger als 0,01 % des Streubesitzes ausmacht.

In der Meldung wird David Buonasera als verkaufender Aktionär genannt, der in den letzten drei Monaten bereits 12.395 Aktien für Bruttoerlöse von 194.776,59 $ veräußert hat. Obwohl die Dollarbeträge im Vergleich zur Marktkapitalisierung von Magnite gering sind, können aufeinanderfolgende Insiderverkäufe bei einigen Investoren Bedenken hervorrufen. Das Formular enthält keine operativen oder finanziellen Leistungsdaten und macht keine Aussagen zu den Fundamentaldaten von Magnite; es offenbart lediglich die Verkaufsabsicht des Insiders gemäß Regel 144.

Positive
  • None.
Negative
  • Insider continues to sell shares, potentially signaling reduced personal confidence although amounts are immaterial.

Insights

TL;DR: Small, routine Rule 144 sale; sentiment slightly negative but immaterial financially.

The transaction involves 9,289 shares, following two earlier sales in May totaling 12,395 shares. Cumulatively, the insider will have sold about 21,684 shares—still an insignificant fraction of Magnite’s ~141 million shares outstanding. Because no additional context (e.g., option expirations, tax obligations) is provided, investors may view the pattern as mild bearish sentiment from the insider. However, the dollar value is too small to affect liquidity or ownership structure. I classify the filing as not impactful for valuation, but worth noting in governance tracking.

Magnite, Inc. (MGNI) ha depositato un Modulo 144 indicando la prevista vendita di 9.289 azioni ordinarie per un valore approssimativo di 204.358 $ al prezzo di mercato corrente. Le azioni sono state originariamente acquisite il 15/02/2024 come azioni vincolate direttamente dall'emittente e la vendita sarà eseguita tramite Morgan Stanley Smith Barney LLC intorno al 30/06/2025. Le azioni totali in circolazione sono riportate pari a 141.110.559, quindi la vendita proposta rappresenta meno dello 0,01% del flottante.

Il deposito indica David Buonasera come azionista venditore, che ha già ceduto 12.395 azioni negli ultimi tre mesi per un ricavo lordo di 194.776,59 $. Sebbene gli importi in dollari siano modesti rispetto alla capitalizzazione di mercato di Magnite, vendite consecutive da parte di insider possono generare preoccupazioni tra alcuni investitori. Il modulo non contiene dati operativi o finanziari né affermazioni sui fondamentali di Magnite; si limita a divulgare l’intenzione dell’insider di vendere ai sensi della Regola 144.

Magnite, Inc. (MGNI) presentó un Formulario 144 indicando una venta planificada de 9,289 acciones comunes por un valor aproximado de $204,358 al precio de mercado vigente. Las acciones fueron adquiridas originalmente el 15/02/2024 como acciones restringidas directamente del emisor y se ejecutarán a través de Morgan Stanley Smith Barney LLC alrededor del 30/06/2025. El total de acciones en circulación se reporta en 141,110,559, por lo que la venta propuesta representa menos del 0.01% del flotante.

El documento lista a David Buonasera como el accionista vendedor, quien ya ha vendido 12,395 acciones en los últimos tres meses por ingresos brutos de $194,776.59. Aunque las cantidades en dólares son modestas en relación con la capitalización de mercado de Magnite, ventas consecutivas por parte de insiders pueden generar preocupaciones en algunos inversores. El formulario no contiene datos operativos o financieros ni hace afirmaciones sobre los fundamentos de Magnite; simplemente revela la intención del insider de vender bajo la Regla 144.

Magnite, Inc. (MGNI)는 9,289주의 보통주를 약 $204,358 상당으로 매도할 계획임을 나타내는 Form 144를 제출했습니다. 해당 주식은 2024년 2월 15일 발행사로부터 직접 제한 주식으로 취득되었으며, 2025년 6월 30일경 Morgan Stanley Smith Barney LLC를 통해 매도될 예정입니다. 총 발행 주식 수는 141,110,559주로 보고되어 있으며, 이번 매도는 유통 주식의 0.01% 미만에 해당합니다.

신고서에는 매도 주주로 David Buonasera가 명시되어 있으며, 그는 지난 3개월 동안 이미 12,395주를 매도하여 총 $194,776.59의 수익을 올렸습니다. 금액은 Magnite의 시가총액에 비해 적은 편이지만, 연속적인 내부자 매도는 일부 투자자들에게 우려를 불러일으킬 수 있습니다. 이 양식은 운영 또는 재무 성과 데이터가 포함되어 있지 않으며, Magnite의 기본적인 사항에 대해 어떠한 주장도 하지 않고 오로지 내부자의 매도 의도를 Rule 144에 따라 공개합니다.

Magnite, Inc. (MGNI) a déposé un formulaire 144 indiquant la vente prévue de 9 289 actions ordinaires d'une valeur d'environ 204 358 $ au prix du marché en vigueur. Les actions ont été initialement acquises le 15/02/2024 en tant qu'actions restreintes directement auprès de l'émetteur et seront vendues via Morgan Stanley Smith Barney LLC aux alentours du 30/06/2025. Le nombre total d'actions en circulation est rapporté à 141 110 559, ce qui signifie que la vente proposée représente moins de 0,01 % du flottant.

Le document mentionne David Buonasera comme actionnaire vendeur, qui a déjà cédé 12 395 actions au cours des trois derniers mois pour un produit brut de 194 776,59 $. Bien que les montants en dollars soient modestes par rapport à la capitalisation boursière de Magnite, des ventes consécutives d'initiés peuvent susciter des inquiétudes chez certains investisseurs. Le formulaire ne contient aucune donnée opérationnelle ou financière et ne fait aucune déclaration sur les fondamentaux de Magnite ; il se limite à divulguer l'intention de l'initié de vendre conformément à la règle 144.

Magnite, Inc. (MGNI) hat ein Formular 144 eingereicht, das einen geplanten Verkauf von 9.289 Stammaktien im Wert von etwa 204.358 $ zum aktuellen Marktpreis anzeigt. Die Aktien wurden ursprünglich am 15.02.2024 als eingeschränkte Aktien direkt vom Emittenten erworben und sollen etwa am 30.06.2025 über Morgan Stanley Smith Barney LLC verkauft werden. Die Gesamtzahl der ausstehenden Aktien wird mit 141.110.559 angegeben, sodass der geplante Verkauf weniger als 0,01 % des Streubesitzes ausmacht.

In der Meldung wird David Buonasera als verkaufender Aktionär genannt, der in den letzten drei Monaten bereits 12.395 Aktien für Bruttoerlöse von 194.776,59 $ veräußert hat. Obwohl die Dollarbeträge im Vergleich zur Marktkapitalisierung von Magnite gering sind, können aufeinanderfolgende Insiderverkäufe bei einigen Investoren Bedenken hervorrufen. Das Formular enthält keine operativen oder finanziellen Leistungsdaten und macht keine Aussagen zu den Fundamentaldaten von Magnite; es offenbart lediglich die Verkaufsabsicht des Insiders gemäß Regel 144.

false000149229800014922982025-06-302025-06-30

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 30, 2025
SABRA HEALTH CARE REIT, INC.
(Exact name of registrant as specified in its charter)
 
Maryland 001-34950 27-2560479
(State of
Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
1781 Flight Way
Tustin
CA
92782
(Address of principal executive offices)(Zip Code)
Registrant's telephone number including area code: (888393-8248  
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01
Other Events.
On June 30, 2025, Sabra Health Care REIT, Inc. (the “Company”) announced that its subsidiary, Sabra Health Care Limited Partnership (the “Limited Partnership”), will redeem all $500 million aggregate principal amount of its outstanding 5.125% Senior Notes due 2026 (the “Notes”) on July 31, 2025 (the “Redemption Date”).
On the Redemption Date, in accordance with the terms of the Notes, and the indenture and supplemental indentures governing the Notes (collectively, the “Indenture”), the Limited Partnership will redeem all outstanding Notes at a redemption price (the “Redemption Price”) equal to (i) 100% of their principal amount, together with accrued and unpaid interest thereon, if any, to (but excluding) the Redemption Date, plus (ii) the Make-Whole Amount (as such term is defined in the Notes). Effective as of the Redemption Date, interest will cease to accrue on the Notes, all Notes will cease to be outstanding and the Holders of the Notes shall have no right in respect of such Notes except the right to receive the Redemption Price thereof.
The Limited Partnership intends to fund the redemption by issuing a $500 million term loan.
At the Limited Partnerships request, a notice of redemption of all outstanding Notes has been sent by the indenture trustee for the Notes to all currently registered holders of the Notes. This Current Report on Form 8-K does not constitute a notice of redemption under the Indenture.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
SABRA HEALTH CARE REIT, INC.
Date: June 30, 2025/S/ MICHAEL COSTA
Name: Michael Costa
Title: Chief Financial Officer, Secretary and
Executive Vice President




FAQ

What is Magnite (MGNI) disclosing in this Form 144?

The company reports an insider’s plan to sell 9,289 common shares worth about $204k on or after 06/30/2025.

Who is selling the shares according to the filing?

David Buonasera is listed as the selling shareholder under Rule 144.

How many Magnite shares has the insider sold recently?

The insider sold 12,395 shares in May 2025 and now plans to sell an additional 9,289 shares.

What percentage of Magnite’s outstanding shares does the planned sale represent?

Less than 0.01 % of the 141,110,559 shares outstanding.

Does the filing include any financial performance data?

No, Form 144 only details the intended sale; it contains no earnings or operational metrics.
Sabra Health Care Reit Inc

NASDAQ:SBRA

SBRA Rankings

SBRA Latest News

SBRA Latest SEC Filings

SBRA Stock Data

4.41B
234.89M
1.3%
100.6%
7.16%
REIT - Healthcare Facilities
Real Estate Investment Trusts
Link
United States
TUSTIN